Publications by authors named "M Iglarz"
Introduction: Cerebral blood flow (CBF) is reduced in patients with Alzheimer's disease (AD). Flow-mediated dilation (FMD), which plays a key role in the regulation of blood flow, is attenuated by endothelin-1. We hypothesized that endothelin receptor blockade may improve CBF in AD.
View Article and Find Full Text PDFPulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or in combination on the RV and plasma metabolomics in SuHx and PAB models.
View Article and Find Full Text PDFArticle Synopsis
- - Aprocitentan is being tested as a new oral medication to help manage difficult hypertension and its effects on weight gain were studied in healthy participants on a high-sodium diet.
- - In a double-blind study with 28 subjects, those taking aprocitentan showed weight increases compared to placebo, with gains of up to 0.83 kg at the highest dose (50 mg/day).
- - Despite the weight gain, there was no clear evidence of sodium retention; instead, plasma volume rose slightly, and urinary sodium excretion decreased at lower doses.
Objective: Organic nitrates such as isosorbide-5-mononitrate (ISMN) and isosorbide dinitrate (ISDN) are used for the treatment of patients with chronic symptomatic stable coronary artery disease and chronic congestive heart failure. Limiting side effects of these nitrovasodilators include nitrate tolerance and/or endothelial dysfunction mediated by oxidative stress. Here, we tested the therapeutic effects of the dual endothelin (ET) receptor antagonist macitentan in ISMN- and ISDN-treated animals.
View Article and Find Full Text PDFArticle Synopsis
- * Aprocitentan, a dual ET receptor antagonist, was tested and found to reduce blood pressure (BP) more efficiently in low-renin rats compared to normal renin rats, demonstrating lasting effects.
- * When combined with RAS blockers, aprocitentan was more effective in lowering BP compared to spironolactone, and it did so without causing kidney damage, suggesting its potential as a safer hypertension treatment.